179 related articles for article (PubMed ID: 8639790)
1. Altered expression of Pax-5 gene in human myeloma cells.
Mahmoud MS; Huang N; Nobuyoshi M; Lisukov IA; Tanaka H; Kawano MM
Blood; 1996 May; 87(10):4311-5. PubMed ID: 8639790
[TBL] [Abstract][Full Text] [Related]
2. Altered mRNA expression of Pax5 and Blimp-1 in B cells in multiple myeloma.
Borson ND; Lacy MQ; Wettstein PJ
Blood; 2002 Dec; 100(13):4629-39. PubMed ID: 12453881
[TBL] [Abstract][Full Text] [Related]
3. [Pax-5 genes and CD19 molecules in human myeloma].
Ishikawa H; Kawano M
Rinsho Ketsueki; 2000 May; 41(5):404-7. PubMed ID: 10879100
[No Abstract] [Full Text] [Related]
4. Transcription factors Xbp-1, Blimp-1, and BSAP are involved in the regulation of plasmacytic differentiation induced by 2-methoxyestradiol in myeloma cell lines.
Jiang H; Gao W; Sze DM; Xiong H; Hou J
Int J Hematol; 2007 Dec; 86(5):429-37. PubMed ID: 18192112
[TBL] [Abstract][Full Text] [Related]
5. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas.
Krenacs L; Himmelmann AW; Quintanilla-Martinez L; Fest T; Riva A; Wellmann A; Bagdi E; Kehrl JH; Jaffe ES; Raffeld M
Blood; 1998 Aug; 92(4):1308-16. PubMed ID: 9694719
[TBL] [Abstract][Full Text] [Related]
6. Expression of transcription factors Pu.1, Spi-B, Blimp-1, BSAP and oct-2 in normal human plasma cells and in multiple myeloma cells.
Nagy M; Chapuis B; Matthes T
Br J Haematol; 2002 Feb; 116(2):429-35. PubMed ID: 11841448
[TBL] [Abstract][Full Text] [Related]
7. Identification of BSAP (Pax-5) target genes in early B-cell development by loss- and gain-of-function experiments.
Nutt SL; Morrison AM; Dörfler P; Rolink A; Busslinger M
EMBO J; 1998 Apr; 17(8):2319-33. PubMed ID: 9545244
[TBL] [Abstract][Full Text] [Related]
8. Disruption of the B-cell specific transcriptional program in HHV-8 associated primary effusion lymphoma cell lines.
Arguello M; Sgarbanti M; Hernandez E; Mamane Y; Sharma S; Servant M; Lin R; Hiscott J
Oncogene; 2003 Feb; 22(7):964-73. PubMed ID: 12592383
[TBL] [Abstract][Full Text] [Related]
9. Quantitation of multiple myeloma oncogene 1/interferon-regulatory factor 4 gene expression in malignant B-cell proliferations and normal leukocytes.
Yamada M; Asanuma K; Kobayashi D; Moriai R; Yajima T; Yagihashi A; Yamamori S; Watanabe N
Anticancer Res; 2001; 21(1B):633-8. PubMed ID: 11299818
[TBL] [Abstract][Full Text] [Related]
10. The role of BSAP (Pax-5) in B-cell development.
Busslinger M; Urbánek P
Curr Opin Genet Dev; 1995 Oct; 5(5):595-601. PubMed ID: 8664547
[TBL] [Abstract][Full Text] [Related]
11. Deregulated PAX-5 transcription from a translocated IgH promoter in marginal zone lymphoma.
Morrison AM; Jäger U; Chott A; Schebesta M; Haas OA; Busslinger M
Blood; 1998 Nov; 92(10):3865-78. PubMed ID: 9808580
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of BSAP/Pax-5 inhibits switching to IgA and enhances switching to IgE in the I.29 mu B cell line.
Qiu G; Stavnezer J
J Immunol; 1998 Sep; 161(6):2906-18. PubMed ID: 9743352
[TBL] [Abstract][Full Text] [Related]
13. In vivo footprinting and mutational analysis of the proximal CD19 promoter reveal important roles for an SP1/Egr-1 binding site and a novel site termed the PyG box.
Riva A; Wilson GL; Kehrl JH
J Immunol; 1997 Aug; 159(3):1284-92. PubMed ID: 9233624
[TBL] [Abstract][Full Text] [Related]
14. Reduction in DNA binding activity of the transcription factor Pax-5a in B lymphocytes of aged mice.
Anspach J; Poulsen G; Kaattari I; Pollock R; Zwollo P
J Immunol; 2001 Feb; 166(4):2617-26. PubMed ID: 11160324
[TBL] [Abstract][Full Text] [Related]
15. The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP.
Kozmik Z; Wang S; Dörfler P; Adams B; Busslinger M
Mol Cell Biol; 1992 Jun; 12(6):2662-72. PubMed ID: 1375324
[TBL] [Abstract][Full Text] [Related]
16. The Ah receptor recognizes DNA binding sites for the B cell transcription factor, BSAP: a possible mechanism for dioxin-mediated alteration of CD19 gene expression in human B lymphocytes.
Masten SA; Shiverick KT
Biochem Biophys Res Commun; 1995 Jul; 212(1):27-34. PubMed ID: 7541987
[TBL] [Abstract][Full Text] [Related]
17. CD19 expression and growth inhibition of tumours in human multiple myeloma.
Ishikawa H; Tsuyama N; Mahmoud MS; Fujii R; Abroun S; Liu S; Li FJ; Kawano MM
Leuk Lymphoma; 2002 Mar; 43(3):613-6. PubMed ID: 12002767
[TBL] [Abstract][Full Text] [Related]
18. Enforced CD19 expression leads to growth inhibition and reduced tumorigenicity.
Mahmoud MS; Fujii R; Ishikawa H; Kawano MM
Blood; 1999 Nov; 94(10):3551-8. PubMed ID: 10552966
[TBL] [Abstract][Full Text] [Related]
19. C-MAF oncogene dysregulation in multiple myeloma: frequency and biological relevance.
Rasmussen T; Knudsen LM; Dahl IM; Johnsen HE
Leuk Lymphoma; 2003 Oct; 44(10):1761-6. PubMed ID: 14692531
[TBL] [Abstract][Full Text] [Related]
20. Identification of c-myc promoter-binding protein and X-box binding protein 1 as interleukin-6 target genes in human multiple myeloma cells.
Wen XY; Stewart AK; Sooknanan RR; Henderson G; Hawley TS; Reimold AM; Glimcher LH; Baumann H; Malek LT; Hawley RG
Int J Oncol; 1999 Jul; 15(1):173-8. PubMed ID: 10375612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
